CytoDyn Inc. (OTC: CYDY) Monoclonal antibody for treating HIV and Cancer. Potential FDA approval for HIV in 2019

 

 

 

Nader Pourhassan, Ph.D

 

 

 

 

 

 

 

 

CytoDyn Inc. (OTC: CYDY) CEO Interview with Nader Pourhassan, Ph.D, discussing CytoDyn’s PRO140 monoclonal antibody therapy for HIV and cancer.

The company is at a key inflection point, with potential FDA approval for PRO140 for treating HIV expected in 2019. 

Dr. Pourhassan explains the PRO140 technology, its numerous advantages over current HIV therapies on the market, market potential, as well as expanding PRO140’s indications for treating cancer. 

Investor Presentation

CytoDyn_Investor_Presentation